Protectant Activity of Defibrotide in Cardioplegia Followed by IschernialReperfusion Injury in the Isolated Rat Heart

Rossoni, Giuseppe; Pompilio, Giulio; Biglioli, Paolo; Alamanni, Francesco; Tartara, Paolo; Rona, P; Porqueddu, Massimo; Berti, F.

doi:10.1111/j.1540-8191.1999.tb01005.x

Cited by 4 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A significant result of our study was that none of the 15 patients underwent prophylaxis with defibrotide. Defibrotide is a drug that acts directly on ECs and is used for the prevention and treatment of SOS, ischemia, atherosclerosis and thrombocytopenic purpura, as well as any pathological condition originating from endothelial damage …”

Section: Discussionmentioning

confidence: 99%

Monocyte‐predominant engraftment, cytokine levels and early transplant‐related complications in pediatric hematopoietic stem cell recipients

Maximova

Granzotto²,

Barbieri

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Myeloablative conditioning is a well‐established procedure that precedes hematopoietic stem cell transplantation (HSCT), particularly in pediatric patients. In the period directly following transplantation, several factors may contribute to complications that lead to the activation or damage of endothelial cells, involved in the pathogenesis of vascular endothelial syndromes (VES). However, to date, sufficiently specific and sensitive diagnostic markers for the various forms of VES have not been identified. This was a retrospective single‐center study of patients who underwent allogeneic HSCT. For this cohort of patients, parameters including type of engraftment, donor characteristics, and cytokine production were measured and correlated with a high prevalence of short‐term complications after HSCT. The aim of this study was to identify specific parameters useful for improving diagnostics and predicting adverse effects in VES. We confirmed that monocyte‐predominant engraftment was related to a higher risk for an early transplant‐related complication termed sinusoidal obstruction syndrome (SOS). The increased production of specific cytokines, in particular RANTES, represents a marker associated with prevalent engraftment. In addition, patients undergoing prophylaxis with defibrotide had “classical” engraftment, a common cytokine profile and a lower incidence of life‐threatening transplant‐related complications. The beneficial effect of defibrotide might be a starting point for developing selective prophylaxis for patients with monocyte engraftment to prevent severe early transplant‐related complications.

show abstract

Section: Discussionmentioning

confidence: 99%

Monocyte‐predominant engraftment, cytokine levels and early transplant‐related complications in pediatric hematopoietic stem cell recipients

Maximova

Granzotto²,

Barbieri

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

show abstract

Prostacyclin Reduces Incidence of Myocardial Damage After Coronary Endarterectomy

Jonjev

Nicin

Mujovic

et al. 2004

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

Defibrotide: Properties and clinical use of an old/new drug

Pescador

Capuzzi

Mantovani

et al. 2013

Vascular Pharmacology

103

View full text Add to dashboard Cite

The drug named defibrotide (DFT) has been studied for many years. It has been shown to possess many activities: profibrinolytic, antithrombotic-thrombolytic, antiischemic (heart, liver, kidney, skin, brain), antishock, antiatherosclerotic, antirejection and anti-angiogenic. The previously displayed activities, as antithrombotic, profibrinolytic and anti-inflammatory, suggested its use in vascular disorders, as in the treatment of peripheral obliterative arterial disease and in thrombophlebitis. Some years after, the use of DFT in hepatic veno-occlusive disease has been also proposed. Even if DFT was considered for long time a multi-target drug, now it could be considered on the whole as a drug able to protect endothelium against activation. The present work reviews the more important experimental and clinical studies performed to detect DFT effects.

show abstract

Protectant Activity of Defibrotide in Cardioplegia Followed by IschernialReperfusion Injury in the Isolated Rat Heart

Cited by 4 publications

References 15 publications

Monocyte‐predominant engraftment, cytokine levels and early transplant‐related complications in pediatric hematopoietic stem cell recipients

Monocyte‐predominant engraftment, cytokine levels and early transplant‐related complications in pediatric hematopoietic stem cell recipients

Prostacyclin Reduces Incidence of Myocardial Damage After Coronary Endarterectomy

Defibrotide: Properties and clinical use of an old/new drug

Contact Info

Product

Resources

About